Mark Mulligan, MD, FIDSA
Distinguished Professor of Medicine
Division of Infectious Diseases
The Hope Clinic of the Emory Vaccine Center
Emory Vaccinology Training Program (NIAID T32)
Emory Vaccine and Treatment Evaluation Unit (NIAID VTEU)
Associate Director for Clinical Trials
Emory Vaccine Center
After medical school and internal medicine residency, I received training in molecular virology and infectious diseases, as well as clinical trials. My interest in HIV vaccine development then led me to focus on immunology and vaccine trials. My research broadened to include clinical and laboratory studies of other infectious diseases with public health importance, including antimicrobial resistance.
My research program now is focused on translational studies of human immune responses to pathogens and vaccines, and studies of therapeutics for infections. The studies focus particularly on infections for which antimicrobial resistance is a significant problem or for which vaccines do not exist.
I am involved in national and international clinical trials leadership (NIAID-funded Vaccine and Treatment Evaluation Unit [VTEU]) and NIAID-funded HIV Vaccine Trials Network [HVTN]) and in mentoring and training the next generation of infectious diseases research leaders (in the clinic and laboratory, and through the Emory Vaccinology Training Program [NIAID T32]).
Current projects in the laboratory and research clinic related to antimicrobial resistance:
Development of a model human challenge (intradermal BCG) to facilitate TB vaccine research; multiple ascending dose PK/PD study of a novel guanosine analog nucleoside inhibitor for CMV treatment; and treatment of recurrent Clostridium difficile by fecal microbiota replacement via bacterial spores delivered in a capsule.
Other ongoing studies
Human T and B cell responses to: Ebola virus vaccines; seasonal and pandemic influenza A vaccines including H3N2v and H7N9; smallpox vaccines; norovirus challenge; and a novel microneedle influenza vaccine. We are also studying memory B and T cell responses after HPV vaccination; and the blood CD4+ T follicular helper (TFH) cell population as a biomarker of vaccine response.
Early phase HIV vaccine trials; human efficacy trial of a broadly neutralizing monoclonal antibody for HIV prevention; human titration study of a G.II.2 norovirus human challenge stock to facilitate norovirus vaccine development; and a first-ih-humans clinical trial of a novel microneedle influenza vaccine (developed at Georgia Tech and Emory).
- View publications on PubMed